Emergent BioSolutions Signs ~$34.5M Agreement With Substipharm Biologics Over Drug Substance Production For Its Japanese Encephalitis Vaccine

Emergent BioSolutions Inc.

EBS

0.00

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese Encephalitis (JE) vaccine, licensed internationally under the brand name IMOJEV® at Emergent's Canton, Massachusetts facility, and for Emergent to serve as the exclusive distributor of the vaccine to the U.S. government, following potential U.S. Food & Drug Administration (FDA) regulatory endeavors.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.